Clinical trial
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With…
NCT00160693 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00160693 |
|---|---|
| Title | Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis |
| Official title | A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological |
| Interventions | Certolizumab Pegol |
| Enrollment | 402 |
| Start date | Mar 1, 2003 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 1, 2018 |
| Countries | Austria, Belgium, Czechia, Germany, Ireland, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: